Mercer University School of Medicine Researcher Describes Research in Malaria (Targeting Plasmodium Life Cycle with Novel Parasite Ligands as Vaccine Antigens).

A recent study conducted by researchers at Mercer University School of Medicine highlights the urgent need for a more effective malaria vaccine. The World Health Organization (WHO) reported that in 2022, there were an estimated 249 million malaria cases and 608,000 malaria deaths, with 94% of the deaths occurring in Africa and 80% affecting children under the age of 5. The current malaria vaccine, RTS,S/AS01, achieved modest efficacy, reducing mortality by only 13%. The researchers propose targeting specific ligand-receptor interactions in the parasite's life cycle as a potential strategy for developing novel malaria vaccine antigens. [Extracted from the article]

Copyright of Zika & Mosquito Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)